BMRA
Biomerica, Inc.
BMRA trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over BMRA overall, supported by stronger fundamentals and lower modeled downside.
BMRA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
BMRA's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BMRA PE Valuation
BMRA has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BMRA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect BMRA's losses to grow, with revenue declining.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
BMRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.67 | -$0.15 |
| Q2 2026 | -$1.30 | +$0.86 |
| Q1 2026 | -$1.45 | +$0.87 |
| Q4 2025 | -$1.49 | +$1.23 |
| Q3 2025 | -$1.52 | +$1.44 |
| Q2 2025 | -$2.16 | +$0.72 |
| Q1 2025 | -$2.32 | +$0.64 |
| Q4 2024 | -$2.72 | +$0.32 |
BMRA is still losing money, but far less than before: $1.67 per share over the past year, against $4.96 at its worst in mid-2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BMRA on earnings quality, reporting a profit while its opponent remains loss making.
BMRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.3M | -8.3% |
| Q2 2026 | $875K | +17% |
| Q1 2026 | $987K | -12% |
| Q4 2025 | $1.2M | -26% |
| Q3 2025 | $1.4M | -24% |
| Q2 2025 | $749K | -33% |
| Q1 2025 | $1.1M | +10% |
| Q4 2024 | $1.6M | +4.4% |
BMRA's revenue has slid since its 2022 peak: $1M last quarter, down 8.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -97% | -16 points |
| Q2 2026 | -175% | +34 points |
| Q1 2026 | -132% | -23 points |
| Q4 2025 | -113% | -53 points |
| Q3 2025 | -81% | -5.3 points |
| Q2 2025 | -209% | -72 points |
| Q1 2025 | -108% | +89 points |
| Q4 2024 | -61% | +42 points |
BMRA's operating margin was −97% last quarter, down 16 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BMRA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BMRA on profitability, with a higher operating margin.
BMRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$802K | -$534K |
| Q2 2026 | -$912K | -$251K |
| Q2 2025 | -$661K | +$407K |
| Q2 2024 | -$1.1M | -$105.2K |
| Q1 2024 | -$1.8M | -$70.4K |
| Q4 2023 | -$848K | +$389.7K |
| Q3 2023 | -$1.7M | -$88.1K |
| Q2 2023 | -$962.8K | +$3.3M |
BMRA has burned cash in almost every quarter: −$4M over the past year, against −$4M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BMRA on cash generation, producing positive trailing cash flow while its opponent burns cash.
BMRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.5% | +286K shares |
| 1 year | +43% | +999K shares |
| 3 years | +86% | +1.5M shares |
| 5 years | +121% | +1.8M shares |
| Available history | +169% | +2.1M shares |
BMRA has 3M diluted shares, up 43% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BMRA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BMRA Net Leverage
BMRA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
BMRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.0 | Neutral |
| Stochastic | 10.9 | Oversold |
BMRA's weekly RSI is 34 (neutral) and its Stochastic is 11 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BMRA PE vs Healthcare Sector
BMRA has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BMRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.81 | 28% below |
| 20 week MA | $1.83 | 29% below |
| 50 week MA | $2.08 | 38% below |
| 100 week MA | $2.83 | 54% below |
| 200 week MA | $5.62 | 77% below |
BMRA is in a downtrend: it's below all five of its weekly moving averages, and 77% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BMRA on trend strength, trading above more of its moving averages.
BMRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.6 | $39.8 | +84% |
| 2021 | $39.8 | $33.6 | -15% |
| 2022 | $33.6 | $29.7 | -12% |
| 2023 | $29.7 | $10.0 | -66% |
| 2024 | $10.0 | $2.52 | -75% |
| 2025 | $2.52 | $2.70 | +7.1% |
| 2026 YTD | $2.70 | $1.30 | -52% |
BMRA has finished lower in four of the last six years. It's down 52% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BMRA on returns for 2026, with the stronger performance.